Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C49H55FN10O7S |
Molecular Weight | 947.087 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C2=NC=C(N2)C3=CC4=C(C=C3)N5[C@@H](OC6=C(C5=C4)C(F)=CC(=C6)C7=CN=C(N7)[C@@H]8CCCN8C(=O)[C@@H](NC(=O)OC)C(C)C)C9=CN=C(S9)C%10CC%10
InChI
InChIKey=AXWDHVUJXNOWCC-RAEGKSCOSA-N
InChI=1S/C49H55FN10O7S/c1-24(2)40(56-48(63)65-5)45(61)58-15-7-9-34(58)42-51-21-31(54-42)27-13-14-33-29(17-27)19-36-39-30(50)18-28(20-37(39)67-47(60(33)36)38-23-53-44(68-38)26-11-12-26)32-22-52-43(55-32)35-10-8-16-59(35)46(62)41(25(3)4)57-49(64)66-6/h13-14,17-26,34-35,40-41,47H,7-12,15-16H2,1-6H3,(H,51,54)(H,52,55)(H,56,63)(H,57,64)/t34-,35-,40-,41-,47-/m0/s1
Ruzasvir (previously known as MK-8408) was developed as a nonstructural protein 5A (NS5A) inhibitor for the treatment of hepatitis C and hepatitis C infection. Ruzasvir successfully completed phase II clinical trial for combination therapy. The obtained results have shown that ruzasvir in combination with uprifosbuvir was highly effective and well-tolerated in participants infected with hepatitis C virus genotypes GT1, GT2, GT4, GT5, and GT6, with a lower efficacy in GT3-infected persons.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/31108015
All participants received ruzasvir 180 mg plus uprifosbuvir 450 mg once daily for 12 weeks
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C281
Created by
admin on Sat Dec 16 09:51:31 GMT 2023 , Edited by admin on Sat Dec 16 09:51:31 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CD-08
Created by
admin on Sat Dec 16 09:51:31 GMT 2023 , Edited by admin on Sat Dec 16 09:51:31 GMT 2023
|
PRIMARY | |||
|
91936863
Created by
admin on Sat Dec 16 09:51:31 GMT 2023 , Edited by admin on Sat Dec 16 09:51:31 GMT 2023
|
PRIMARY | |||
|
SUB180925
Created by
admin on Sat Dec 16 09:51:31 GMT 2023 , Edited by admin on Sat Dec 16 09:51:31 GMT 2023
|
PRIMARY | |||
|
DB11713
Created by
admin on Sat Dec 16 09:51:31 GMT 2023 , Edited by admin on Sat Dec 16 09:51:31 GMT 2023
|
PRIMARY | |||
|
1613081-64-3
Created by
admin on Sat Dec 16 09:51:31 GMT 2023 , Edited by admin on Sat Dec 16 09:51:31 GMT 2023
|
PRIMARY | |||
|
100000166719
Created by
admin on Sat Dec 16 09:51:31 GMT 2023 , Edited by admin on Sat Dec 16 09:51:31 GMT 2023
|
PRIMARY | |||
|
LX752BD95Y
Created by
admin on Sat Dec 16 09:51:31 GMT 2023 , Edited by admin on Sat Dec 16 09:51:31 GMT 2023
|
PRIMARY | |||
|
10193
Created by
admin on Sat Dec 16 09:51:31 GMT 2023 , Edited by admin on Sat Dec 16 09:51:31 GMT 2023
|
PRIMARY | |||
|
C152277
Created by
admin on Sat Dec 16 09:51:31 GMT 2023 , Edited by admin on Sat Dec 16 09:51:31 GMT 2023
|
PRIMARY |
ACTIVE MOIETY